北交所周观察第二十三期：2025Q1北交所主动基金收益均值超24%，稀缺性与低估值内需标的受青睐

Group 1 - In Q1 2025, 52 companies from the Beijing Stock Exchange entered the top ten holdings of various funds, with a total public fund market value of 6.743 billion yuan [3][8][12] - The top three companies by fund holdings are Jinbo Biological, Tongli Co., and Kait Co., with Jinbo Biological being the most held by 51 funds [3][17] - The North Exchange 50 Index fund size increased to 9.3 billion yuan, reflecting a growing interest in the North Exchange market [3][21] Group 2 - In Q1 2025, 69 out of 103 companies reported positive revenue growth, with 24 companies exceeding 25% growth [3][22] - The average return of 11 active theme funds on the North Exchange was around 24%, outperforming the North Exchange 50 Index's 22% return [12][15] - Seven companies entered the top ten holdings of active theme funds for the first time, including Deyuan Pharmaceutical and Longhong Technology [19][22] Group 3 - The overall PE ratio of the North Exchange A-shares decreased to 45X, indicating a potential valuation adjustment [4][24] - The average daily trading volume for the North Exchange fell to 30.1 billion yuan, suggesting a cooling market sentiment [4][25] - The market is expected to continue its consolidation phase, with opportunities arising post the financial report disclosures [3][4] Group 4 - The report highlights a preference for companies with low valuations and significant growth potential, such as Minshida and Lintai New Materials [3][8] - Investment opportunities are suggested in sectors like high-end manufacturing, infrastructure, and specialty consumer goods [3][8][19] - The report emphasizes the alignment of the North Exchange's "specialized, refined, unique, and innovative" positioning with national policies on self-reliance and innovation-driven development [3][4]